Exelixis Inc. buy Quitte
Start price
01.03.16
/
50%
€3.78
Target price
25.04.16
€4.21
Performance (%)
11.80%
End price
25.04.16
€4.23
Summary
This prediction ended on 25.04.16 with a price of €4.23. The prediction had a final performance of 11.80%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Exelixis Inc. | 4.493% | 4.493% | 21.887% | 166.370% |
| iShares Core DAX® | 0.224% | 2.031% | 21.399% | 71.886% |
| iShares Nasdaq 100 | 0.371% | -0.955% | 5.637% | 113.046% |
| iShares Nikkei 225® | 0.972% | -0.953% | 13.432% | 47.267% |
| iShares S&P 500 | 0.417% | -0.622% | 3.310% | 68.687% |
Comments by Quitte for this prediction
In the thread Exelixis Inc. diskutieren
gute Zahlen
Exelixis, Inc. (NASDAQ:EXEL) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03, MarketBeat reports. The company had revenue of $9.94 million for the quarter, compared to analyst estimates of $8.16 million. Exelixis’s revenue for the quarter was up 35.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) earnings per share.